Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) – Pipeline Review, H2 2016’, provides in depth analysis on Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)

The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Cyclacel Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Onconova Therapeutics, Inc.

Vichem Chemie Research Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) Overview 7

Therapeutics Development 8

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Products under Development by Stage of Development 8

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Products under Development by Therapy Area 9

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Products under Development by Indication 10

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Products under Development by Companies 15

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Products under Development by Universities/Institutes 18

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Companies Involved in Therapeutics Development 25

BIND Therapeutics, Inc. 25

Boehringer Ingelheim GmbH 26

Cyclacel Pharmaceuticals, Inc. 27

F. Hoffmann-La Roche Ltd. 28

Onconova Therapeutics, Inc. 29

Vichem Chemie Research Ltd. 30

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Drug Profiles 31

BIND-747 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CYC-140 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

LS-008 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

P-937 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

rigosertib sodium - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

RO-5203280 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecule to Inhibit PLK1 for Cancer - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule to Inhibit PLK1 for Oncology and Bacterial Infections - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

volasertib trihydrochloride - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Dormant Projects 54

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Discontinued Products 57

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Featured News & Press Releases 58

Jun 13, 2016: Onconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting 58

Jun 06, 2016: Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting 58

May 31, 2016: Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting 59

Apr 21, 2016: Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell 59

Mar 21, 2016: Onconova Enrolls First Patient in Europe for Phase 3 INSPIRE Trial of Rigosertib in Higher-Risk Myelodysplastic Syndromes 60

Mar 09, 2016: Onconova Announces Publication of Rigosertib Phase 3 ONTIME Data in Lancet Oncology 60

Jan 11, 2016: NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies 61

Dec 28, 2015: SymBio starts Global Phase 3 Trial for IV Rigosertib 62

Dec 07, 2015: Onconova Enrolls First Patient in Phase 3 INSPIRE Trial of Rigosertib 62

Dec 07, 2015: Onconova Presents Positive Data From Phase 2 Combination Trial of Oral Rigosertib and Azacitidine in Higher-Risk Myelodysplastic Syndromes at 2015 ASH Annual Meeting 63

Oct 30, 2015: Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS 65

Aug 27, 2015: Onconova Therapeutics Files European Clinical Trial Applications for Global Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes 65

Aug 13, 2015: Onconova Therapeutics Announces Submission of Investigational New Drug Application for Pivotal Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes 66

Jun 26, 2015: Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS 66

Jun 15, 2015: Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting 66

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by BIND Therapeutics, Inc., H2 2016 25

Pipeline by Boehringer Ingelheim GmbH, H2 2016 26

Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 27

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 28

Pipeline by Onconova Therapeutics, Inc., H2 2016 29

Pipeline by Vichem Chemie Research Ltd., H2 2016 30

Dormant Projects, H2 2016 54

Dormant Projects (Contd..1), H2 2016 55

Dormant Projects (Contd..2), H2 2016 56

Discontinued Products, H2 2016 57

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports